ArticleClinical and translational radiation oncology2026
Photon-counting CT for radiotherapy: Qualitative assessment of potential clinical value by semi-structured expert interviews.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Photon-counting CT (PCCT) has several potential benefits that can considerably improve the radiotherapy workflow, like availability of intrinsic spectral data and high resolution imaging. It is unknown which treatment sites in radiotherapy will benefit the most from PCCT. This study aimed to identify clinical applications and treatment sites where PCCT may have the most clinical value. Materials and methods: Semi-structured interviews with expert teams were conducted about eight treatment sites. Each expert team consisted of 2 radiation oncologists and 1 radiologist with expertise in specific treatment site. During each session, PCCT images were shown to demonstrate specific PCCT features: instantly changing the energy from 40 to 190 keV with a slider, iodine maps, contrast-agent removal and high-resolution images. Next, the experts scored ten statements about clinical applications for added clinical value on a 5-point Likert scale, from 0=No added clinical value to 4 = Indispensable for the clinic. Results: A total of 80 scores were collected about ten statements and eight treatment sites. The statements about the use of spectral data scored highest for added clinical value, while reducing imaging dose scored lowest. The radiotherapy treatment sites with the highest scores were bone, head and neck and lung tumors, while lowest was prostate where no added value was found. Conclusion: Semi-structured interviews identified advantages of PCCT that may have the most added clinical value for radiotherapy: the use of spectral data and increased resolution. Head and neck, bone and lung tumors are the clinical applications which were scored highest in terms of added clinical value and these could therefore be the first areas for clinical implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.